Safety and efficacy of intravenous colistin (colistin methanesulphonate) for severe multidrug-resistant Gram-negative bacterial infections
CY Cheng, WH Sheng, JT Wang, YC Chen… - International journal of …, 2010 - Elsevier
Multidrug-resistant (MDR) bacterial infections are increasing in Taiwan hospitals, prompting
the common use of colistin. In this study, the safety and efficacy of intravenous (iv) colistin
was assessed. The medical records of patients receiving colistin for treatment of MDR Gram-
negative bacterial infections between January 2006 and September 2008 at a Taiwan
medical centre were reviewed retrospectively. Demographics, clinical presentation,
causative organism, adverse events and outcomes were recorded. Of the 115 patient …
the common use of colistin. In this study, the safety and efficacy of intravenous (iv) colistin
was assessed. The medical records of patients receiving colistin for treatment of MDR Gram-
negative bacterial infections between January 2006 and September 2008 at a Taiwan
medical centre were reviewed retrospectively. Demographics, clinical presentation,
causative organism, adverse events and outcomes were recorded. Of the 115 patient …
Safety and efficacy of intravenous colistin (colistin methanesulphonate) for severe multidrug-resistant Gram-negative bacterial infections.
CCY Cheng ChienYu, SWH Sheng WangHuei… - 2010 - cabidigitallibrary.org
Multidrug-resistant (MDR) bacterial infections are increasing in Taiwan hospitals, prompting
the common use of colistin. In this study, the safety and efficacy of intravenous (iv) colistin
was assessed. The medical records of patients receiving colistin for treatment of MDR Gram-
negative bacterial infections between January 2006 and September 2008 at a Taiwan
medical centre were reviewed retrospectively. Demographics, clinical presentation,
causative organism, adverse events and outcomes were recorded. Of the 115 patient …
the common use of colistin. In this study, the safety and efficacy of intravenous (iv) colistin
was assessed. The medical records of patients receiving colistin for treatment of MDR Gram-
negative bacterial infections between January 2006 and September 2008 at a Taiwan
medical centre were reviewed retrospectively. Demographics, clinical presentation,
causative organism, adverse events and outcomes were recorded. Of the 115 patient …